Physician profile
Nilma Malik
NPI 1417340704
$737.96
in general payments reported to CMS, 2019-2025
14 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $14.46 · 2021: $26.24 · 2023: $27.16 · 2024: $162 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.21 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $160.19 | 2019-2025 | Tepezza |
| Mannkind Corporation | $133.40 | 2025 | |
| Baxter Healthcare | $120.27 | 2024 | |
| Lilly USA, LLC | $47.82 | 2025 | Mounjaro |
| Beta Bionics, INC. | $45.54 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $40.29 | 2024-2025 | Korlym |
| Abbott Laboratories | $34.72 | 2025 | Freestyle Libre 3 |
| Integra Lifesciences Corporation | $27.16 | 2023 | Tenoglide |
| Smith+Nephew, INC. | $26.24 | 2021 | |
| Averitas Pharma INC. | $22.50 | 2024 | Qutenza |
| Dexcom, INC. | $22.38 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $21.16 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.58 | 2025 | Gvoke Hypopen |
| Novo Nordisk INC | $16.71 | 2025 | Ozempic, Rybelsus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilma Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.